Abstract
Etravirine is an enzyme inducer and could lower the concentration of combined drugs. Ten HIV-1-infected patients with multiple treatment failure received raltegravir (400 mg, twice daily) and darunavir/ritonavir (600/100 mg, twice daily). Addition of etravirine (200 mg, twice daily) leads to a significant increase in raltegravir and darunavir trough concentrations (405 vs. 118 and 3837 vs. 2241 ng/ml) and darunavir area under the curve (AUC(12h)) (50 083 vs. 36 277 ng h/ml). All pharmacokinetic parameters appeared to be highly variable regardless to the addition of etravirine.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Darunavir
-
Drug Combinations
-
Female
-
HIV Infections / drug therapy*
-
HIV Infections / metabolism
-
HIV Protease Inhibitors / administration & dosage
-
HIV Protease Inhibitors / pharmacokinetics*
-
HIV-1*
-
Humans
-
Male
-
Middle Aged
-
Nitriles
-
Pyridazines / administration & dosage
-
Pyridazines / pharmacokinetics*
-
Pyrimidines
-
Ritonavir / administration & dosage
-
Ritonavir / pharmacokinetics*
-
Sulfonamides / administration & dosage
-
Sulfonamides / pharmacokinetics*
-
Young Adult
Substances
-
Drug Combinations
-
HIV Protease Inhibitors
-
Nitriles
-
Pyridazines
-
Pyrimidines
-
Sulfonamides
-
etravirine
-
Ritonavir
-
Darunavir